JUL 04, 2018 02:11 AM PDT

First Drug Approved for The Treatment of Hyperhidrosis

WRITTEN BY: Nouran Amin

Hyperhidrosis is a chronic skin condition that results in the increased production of sweat than needed. A certain amount of sweat is normally produced to regulate body temperature, an excess of sweat becomes unnecessary.

Now, the U.S. Food and Drug Administration (FDA) has approved the first drug developed to reduce excessive sweating. The drug will particularly be effective in one type of hyperhidrosis caused under the armpit, better known as primary axillary hyperhidrosis.

According to the drug manufacturing California-based pharmaceutical company, Dermira Inc, the drug which is now known as Qbrexza and will be available in pharmacies in October 2018.

Affected individuals prescribed Qbrexza will receive it as a drug packed inside a cloth. They will be able to use it to wipe over their skin every day to block the sweat glands from activating and thus no sweat will be released from the treated area.

Roughly 15 million Americans experience some form of excessive sweating, with more than 10 million individuals experiencing excessive underarm perspiration.

Excessive sweating is often associated with social embarrassment and emotional burdens to affected individuals. Such distress due to this skin condition has inspired dermatologists to seek effective treatment options.

“From the start, our goal was to develop an approach that went beyond masking a person’s excessive underarm sweating and instead focused on treating the condition in a clinically meaningful way," says Derira Chairman Tom Wiggans.

The FDA approval of Qbrexza was based on two clinical trials.

Most frequent noted side effects of Qbrexza include dry mouth, dilated pupils, sore throat, headache, urinary hesitation, blurred vision, dry nose, dry eyes, dry skin and constipation.

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
HIV Therapeutics Places Risk of Neural Tube Defects
In a study published in the New England Journal of Medicine, women taking an HIV therapeutic drug containing dolutegravir have a higher risk of giving birt...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Chemotherapeutics react differently to radiation
Patients with various types of cancer are almost always treated with a combination of chemotherapy and radiotherapy. In chemotherapy, therapeutics consist ...
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
What does MDMA Therapy Look Like?
The Multidisciplinary Association for Psychedelic Studies (MAPS) aims to create an FDA-approved standardized MDMA-assisted psychotherapy practice for PTSD ...
OCT 13, 2019
Microbiology
OCT 13, 2019
The Long Evolutionary History of Antibiotics and Resistance
The world is full of bacteria that have to share the world with myriad species, and often have to live in competition with other microbes....
OCT 13, 2019
Drug Discovery & Development
OCT 13, 2019
Promising Drug for Prostate Cancer
Using high-throughput screening methods, cancer researchers from the UK have identified some promising drug candidates to test thousands of molecules. Spec...
OCT 13, 2019
Cardiology
OCT 13, 2019
Heart Attacks Without The Risk
Following a heart attack, as the heart heals, scar tissue forms. This issue is less flexible than healthy heart tissue and may encumber the heart's abi...
Loading Comments...